NO20074654L - Lenteviral-vektorer og deres anvendelse - Google Patents
Lenteviral-vektorer og deres anvendelseInfo
- Publication number
- NO20074654L NO20074654L NO20074654A NO20074654A NO20074654L NO 20074654 L NO20074654 L NO 20074654L NO 20074654 A NO20074654 A NO 20074654A NO 20074654 A NO20074654 A NO 20074654A NO 20074654 L NO20074654 L NO 20074654L
- Authority
- NO
- Norway
- Prior art keywords
- vectors
- lentiviral vectors
- gene
- sequences
- lentivirus vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 241000713666 Lentivirus Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65338605P | 2005-02-16 | 2005-02-16 | |
| US66031005P | 2005-03-10 | 2005-03-10 | |
| US68205905P | 2005-05-18 | 2005-05-18 | |
| US72376805P | 2005-10-05 | 2005-10-05 | |
| PCT/US2006/005431 WO2006089001A2 (fr) | 2005-02-16 | 2006-02-16 | Vecteurs lentiviraux et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074654L true NO20074654L (no) | 2007-11-16 |
Family
ID=36917037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074654A NO20074654L (no) | 2005-02-16 | 2007-09-12 | Lenteviral-vektorer og deres anvendelse |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080254008A1 (fr) |
| EP (2) | EP1858332A4 (fr) |
| JP (2) | JP2008538174A (fr) |
| KR (1) | KR20070114157A (fr) |
| AU (1) | AU2006214278C1 (fr) |
| CA (1) | CA2597928A1 (fr) |
| MX (1) | MX2007010008A (fr) |
| NO (1) | NO20074654L (fr) |
| WO (1) | WO2006089001A2 (fr) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7862810B2 (en) * | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| CA2646536A1 (fr) | 2006-04-06 | 2007-10-11 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
| JP2010505442A (ja) * | 2006-10-10 | 2010-02-25 | ビロメッド カンパニー， リミテッド | 安全性の改善された発現ベクター |
| JP2010512782A (ja) * | 2006-12-20 | 2010-04-30 | ジ チャン ユウ， | Ｈｉｖのｎｃ蛋白質発現用ベクター及びこれを利用したｎｃ蛋白質の生産方法 |
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| WO2010051521A1 (fr) * | 2008-10-31 | 2010-05-06 | Lentigen Corporation | Produit de thérapie cellulaire pour le traitement de l'infection par le vih |
| RU2012140691A (ru) * | 2009-03-13 | 2014-03-27 | Лентиген Корпорейшен | Вакцины на основе неинтегрирующегося ретровирусного вектора |
| US20120027725A1 (en) * | 2009-11-30 | 2012-02-02 | Galvin Jeffrey A | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer |
| US20120260355A1 (en) * | 2009-12-22 | 2012-10-11 | The Trustees Of Columbia University In The City Of New York | Method for Evaluating Inhibitory Polynucleotide Efficiency and Efficacy |
| KR20150029756A (ko) | 2011-06-10 | 2015-03-18 | 블루버드 바이오, 인코포레이티드. | 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터 |
| WO2013090409A1 (fr) * | 2011-12-12 | 2013-06-20 | The Children's Hospital Of Philadelphia | Système de production d'un vecteur lentiviral commercial à grande échelle et vecteurs ainsi obtenus |
| WO2015077717A1 (fr) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn |
| WO2015085147A1 (fr) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| EP3137100B1 (fr) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation |
| JP6754761B2 (ja) * | 2014-07-11 | 2020-09-16 | セルジーン コーポレイション | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| EP3212788A2 (fr) | 2014-10-27 | 2017-09-06 | The Broad Institute, Inc. | Compositions, procédés et utilisation de criblage létal synthétique |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| EP3234130B1 (fr) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Procédé pour profiler le répertoire de récepteurs de cellulles t. |
| IL294183B2 (en) | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| EP3319631A4 (fr) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | Pré-immunisation et immunothérapie du vih |
| JP7034065B2 (ja) * | 2015-09-30 | 2022-03-11 | ヴィセリックス・インコーポレーティッド | ナチュラルキラー細胞、造血幹細胞及びマクロファージへの強化された遺伝子送達 |
| EP3356520B1 (fr) | 2015-10-02 | 2022-03-23 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Système lentivirale de distribution de protéines guidée par l'édition de l'arn du génome |
| WO2017079269A1 (fr) | 2015-11-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igf2bp1 et/ou igf2bp3 pour traitement |
| RU2639539C2 (ru) * | 2015-12-29 | 2017-12-21 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Репортерная система на основе лентивирусных репортерных конструкций для изучения белок-белковых взаимодействий |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN116064678A (zh) * | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| WO2017139065A1 (fr) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Vaccination et immunothérapie contre le vih |
| WO2017156311A2 (fr) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Vecteurs de combinaison et méthodes de traitement du cancer |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| JP2019513373A (ja) | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| EP3468617A4 (fr) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | Système d'administration viral sans intégration et procédés associés à ce dernier |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (fr) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | Vecteurs viraux pour le traitement de la maladie de parkinson |
| WO2018071295A1 (fr) * | 2016-10-10 | 2018-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Procédés et compositions pour la production inductible de cytokines anti-inflammatoires |
| MX2019008143A (es) | 2017-01-07 | 2020-01-13 | Selecta Biosciences Inc | Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos. |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| US11965892B2 (en) | 2017-02-12 | 2024-04-23 | Biontech Us Inc. | HLA-based methods and compositions and uses thereof |
| KR20260047644A (ko) | 2017-03-30 | 2026-04-08 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| WO2019017940A1 (fr) * | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | Compositions et méthodes associées à des systèmes cellulaires thérapeutiques multimodaux pour le traitement d'une maladie infectieuse |
| EP3687561A4 (fr) | 2017-09-01 | 2021-06-09 | The Australian National University | Molécules immunorégulatrices et leurs utilisations |
| GB201715052D0 (en) * | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| BR112020007157A2 (pt) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | métodos e composições para a atenuação de respostas de igm antivetor de transferência viral |
| EP3696272A1 (fr) * | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Vecteur rétroviral |
| RU2697797C2 (ru) * | 2017-12-28 | 2019-08-19 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro |
| CN112384204B (zh) | 2018-02-26 | 2023-03-14 | 安托瑞斯公司 | 致耐受性脂质体及其使用方法 |
| WO2020018715A1 (fr) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations |
| WO2020034051A1 (fr) * | 2018-08-16 | 2020-02-20 | Immvira Co. Limited | Procédés et compositions pour le traitement de cancers solides et d'une infection microbienne |
| WO2020072700A1 (fr) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Lignées d'allèles uniques d'alh |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| SG11202104337PA (en) | 2018-11-26 | 2021-05-28 | Massachusetts Inst Technology | Compositions and methods for immune tolerance |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| KR20240091046A (ko) | 2018-12-21 | 2024-06-21 | 바이오엔테크 유에스 인크. | Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템 |
| EP3897745A1 (fr) * | 2018-12-23 | 2021-10-27 | CSL Behring LLC | Thérapie génique de cellules souches hématopoïétiques pour le syndrome de wiskott-aldrich |
| CN109735568A (zh) * | 2019-01-28 | 2019-05-10 | 贵州大学 | 稳定表达fgf-1蛋白细胞株的构建方法 |
| EP3962537A1 (fr) | 2019-04-28 | 2022-03-09 | Selecta Biosciences, Inc. | Méthodes de traitement de sujets présentant une immunité préexistante à des vecteurs de transfert viraux |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| WO2021242793A2 (fr) | 2020-05-26 | 2021-12-02 | The Broad Institute, Inc. | Bibliothèques de mini-protéomes artificiels d'acide nucléique |
| US20220025364A1 (en) * | 2020-06-02 | 2022-01-27 | BioPlx, Inc. | Methods for stable genomic integration in recombinant microorganisms |
| KR20230117327A (ko) | 2020-09-03 | 2023-08-08 | 어빈 에스.와이. 첸 | 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터 |
| JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
| TWI758171B (zh) * | 2021-04-28 | 2022-03-11 | 沛爾生技醫藥股份有限公司 | 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法 |
| US20250066741A1 (en) * | 2021-07-30 | 2025-02-27 | The Trustees Of Princeton University | Compositions and methods for transfer using cer1 |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| EP4426829A1 (fr) | 2021-11-01 | 2024-09-11 | Dana-Farber Cancer Institute, Inc. | Bibliothèques de mini-protéomes artificiels d'acide nucléique sélectionnées biologiquement |
| US20250009802A1 (en) | 2021-12-16 | 2025-01-09 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
| WO2023172624A1 (fr) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppresseurs en association avec des agents anti-igm et dosage associé |
| WO2024015892A1 (fr) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Procédés et systèmes faisant intervenir l'immunopeptidome hla-ii pour la découverte d'antigènes |
| WO2024129696A1 (fr) | 2022-12-12 | 2024-06-20 | Retromer Therapeutics Corp. | Constructions lentivirales et aav comprenant un mini-gène sorl1 destiné à être utilisé dans le traitement de maladies neurodégénératives |
| CN116656617A (zh) * | 2023-01-03 | 2023-08-29 | 生物岛实验室 | 一种外泌体及其制备方法和应用 |
| WO2024178386A1 (fr) | 2023-02-24 | 2024-08-29 | Aarhus Universitet | Méthodes de traitement des maladies du trafic endosomal |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| WO2025097055A2 (fr) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions et méthodes d'utilisation de lymphocytes t en immunothérapie |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
| WO1994016060A1 (fr) * | 1993-01-11 | 1994-07-21 | The Trustees Of The University Of Pennsylvania | Mutants de vih destines a la suppression des infections par vih |
| US6051427A (en) | 1993-06-11 | 2000-04-18 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5591264A (en) | 1994-03-22 | 1997-01-07 | Sony Corporation | Spin coating device |
| US5750396A (en) | 1995-05-08 | 1998-05-12 | St. Judes Children's Research Hospital | Stable virus packaging cell lines |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| US5885806A (en) | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| US6207455B1 (en) * | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| CA2304983A1 (fr) | 1997-09-24 | 1999-04-01 | The Regents Of The University Of California | Vecteurs de lentivirus non originaires de primates et systemes d'encapsidation |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| WO2000040741A2 (fr) * | 1999-01-07 | 2000-07-13 | The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health | Systeme de vecteurs lentiviraux |
| US7262049B2 (en) * | 1999-03-16 | 2007-08-28 | Dana-Farber Cancer Institute, Inc. | Pseudotyped lentiviral vectors and uses thereof |
| US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| MXPA02012254A (es) * | 2000-06-23 | 2003-04-25 | American Cyanamid Co | Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre. |
| KR100545945B1 (ko) * | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| CA2413151C (fr) * | 2000-07-03 | 2012-11-27 | Gala Design, Inc. | Cellules hotes contenant de multiples vecteurs d'integration |
| AU2001286540A1 (en) | 2000-08-24 | 2002-03-04 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| US7211247B2 (en) * | 2001-04-09 | 2007-05-01 | University Of Southern California | Lentivirus vectors for gene transfer to alveolar epithelial cells |
| JP2005538685A (ja) * | 2001-12-21 | 2005-12-22 | トランザイム， インコーポレイテッド | レンチウイルスベクターを使用して遺伝的に改変された動物を生成するための方法および組成物 |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| CA2574282A1 (fr) * | 2004-07-21 | 2006-03-02 | Dana-Farber Cancer Institute, Inc. | Vecteurs lentiviraux et utilisations associees |
-
2006
- 2006-02-16 MX MX2007010008A patent/MX2007010008A/es active IP Right Grant
- 2006-02-16 AU AU2006214278A patent/AU2006214278C1/en not_active Ceased
- 2006-02-16 EP EP06735210A patent/EP1858332A4/fr not_active Withdrawn
- 2006-02-16 KR KR1020077021145A patent/KR20070114157A/ko not_active Withdrawn
- 2006-02-16 CA CA002597928A patent/CA2597928A1/fr not_active Abandoned
- 2006-02-16 JP JP2007556283A patent/JP2008538174A/ja active Pending
- 2006-02-16 WO PCT/US2006/005431 patent/WO2006089001A2/fr not_active Ceased
- 2006-02-16 US US11/884,639 patent/US20080254008A1/en not_active Abandoned
- 2006-02-16 EP EP12176017.7A patent/EP2573185A3/fr not_active Withdrawn
-
2007
- 2007-09-12 NO NO20074654A patent/NO20074654L/no not_active Application Discontinuation
-
2012
- 2012-10-24 JP JP2012234688A patent/JP2013059331A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20080254008A1 (en) | 2008-10-16 |
| JP2008538174A (ja) | 2008-10-16 |
| KR20070114157A (ko) | 2007-11-29 |
| EP2573185A2 (fr) | 2013-03-27 |
| MX2007010008A (es) | 2008-01-18 |
| EP1858332A2 (fr) | 2007-11-28 |
| WO2006089001A3 (fr) | 2007-07-12 |
| WO2006089001A2 (fr) | 2006-08-24 |
| AU2006214278A1 (en) | 2006-08-24 |
| AU2006214278C1 (en) | 2012-07-19 |
| EP2573185A3 (fr) | 2013-06-05 |
| JP2013059331A (ja) | 2013-04-04 |
| AU2006214278B2 (en) | 2012-01-19 |
| EP1858332A4 (fr) | 2011-06-22 |
| CA2597928A1 (fr) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074654L (no) | Lenteviral-vektorer og deres anvendelse | |
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| JP2012509340A5 (fr) | ||
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| EA200601946A3 (ru) | Антитела, связывающиеся с белками steap-1, и их производные | |
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| CY1114643T1 (el) | Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων | |
| EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
| JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
| JP2014500249A5 (fr) | ||
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| EP3067417A3 (fr) | Procédés améliorés pour la purification de vecteurs aav recombinants | |
| CY1113560T1 (el) | Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| NO20062876L (no) | Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater | |
| ZA202104912B (en) | Rna encoding a protein | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| WO2010005704A3 (fr) | Nouveaux vecteurs viraux sindbis défectueux, à plasmide assistant, et leurs procédés d'utilisation | |
| WO2006138745A3 (fr) | Peptides et vaccins therapeutiques | |
| DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine | |
| NO20081541L (no) | Ny sjo-lus vaksine | |
| NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
| EP3195882B1 (fr) | Agent antiviral comprenant un oligonucléotide d'arn | |
| PL1951283T3 (pl) | Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |